AbbVie (ABBV) vs. AstraZeneca (AZN)

Company Profile

AbbVie (ABBV) and AstraZeneca (AZN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while AZN is classified in Pharmaceuticals.

Historical Performance

AstraZeneca (AZN) has an aggressive beta of 1.31, indicating higher sensitivity to broad-market moves, while AbbVie (ABBV) is defensive at 0.30 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Historical Performance at a Glance

Profitability

Both AbbVie (ABBV) at 95.59% and AstraZeneca (AZN) at 22.27% rank in the top quartile for Return on Equity (TTM) among industry peers, indicating strong returns on shareholders’ equity.

AstraZeneca (AZN) at 17.19% ranks in the top quartile for Net Profit Margin (TTM), ahead of AbbVie (ABBV) at 6.91%, which sits closer to the industry mid-range.

Both AbbVie (ABBV) at 24.65% and AstraZeneca (AZN) at 23.69% rank in the top quartile for Operating Profit Margin (TTM) among industry peers, indicating both companies convert revenue into operating income more strongly than typical competitors.

Profitability at a Glance

Financial Strength

Both AbbVie (ABBV) at 0.67 and AstraZeneca (AZN) at 0.91 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AstraZeneca (AZN) at 0.72 is around its industry mid-range for Debt-to-Equity Ratio (MRQ), while AbbVie (ABBV) at 49.22 sits above its industry benchmark range, pointing to a heavier debt load relative to equity.

AstraZeneca (AZN) at 12.68 ranks in the top quartile for Interest Coverage Ratio (TTM), ahead of AbbVie (ABBV) at 3.46, which sits around the industry mid-range.

Financial Strength at a Glance

Growth

Revenue Growth

Revenue Growth at a Glance

EPS Growth

EPS Growth at a Glance

Dividend

Both AbbVie (ABBV) at 3.11% and AstraZeneca (AZN) at 1.69% report Dividend Yield (TTM) near their industry mid-ranges, so neither company stands out strongly from peers on cash yield relative to share price.

AbbVie (ABBV) reports an unusual Dividend Payout Ratio (TTM) of 275.84% — outside the typical 0–100% range, indicating either negative earnings (negative ratio) or dividends above current-period earnings (above 100%), both signaling sustainability concerns. Meanwhile AstraZeneca (AZN) reports 47.27%, ranking against industry peers normally.

Dividend at a Glance

Valuation

AstraZeneca (AZN) at 27.96 hovers around the typical industry Price-to-Earnings Ratio (TTM), while AbbVie (ABBV) at 88.76 sits above its industry benchmark range — an elevated trailing earnings multiple for ABBV relative to peers.

Both AbbVie (ABBV) at 6.13 and AstraZeneca (AZN) at 4.81 post Price-to-Sales Ratio (TTM) near the typical industry midpoint — neither company stands out strongly from peers on trailing revenue multiple.

AstraZeneca (AZN) at 6.46 hovers around the typical industry Price-to-Book Ratio (MRQ), while AbbVie (ABBV) at 261.01 sits above its industry benchmark range — an elevated book-value multiple for ABBV relative to peers.

Valuation at a Glance